Search

Displaying results 5041 - 5050 of 9670 in total
  1. Drug

    Drostanolone propionate

    go.drugbank.com/drugs/DB14655
    ApprovedIllicit

  2. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692]

  3. Drug

    Mocetinostat

    go.drugbank.com/drugs/DB11830
    Investigational

    Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

  4. Drug

    Q-Derp1

    go.drugbank.com/drugs/DB05857
    Experimental

    Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.

  5. Drug

    PX-12

    go.drugbank.com/drugs/DB05448
    Investigational

    Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced

  6. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. … Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.

  7. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this

  8. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...

  9. Drug

    Carbomycin

    go.drugbank.com/drugs/DB11383
    ExperimentalVet approved

    The structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965. … This antibacterial is obtained from _Streptomyces halstedii_ and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains.

  10. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]